Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease.
Publication/Presentation Date
1-1-2017
Abstract
INTRODUCTION: Recurrence of gastrointestinal stromal tumors (GISTs) after surgical resection and imatinib mesylate (IM) adjuvant therapy poses a significant treatment challenge. We present the case of a patient who underwent surgical resection after recurrence and review the current literature regarding treatment.
CASE PRESENTATION: A 58-year-old man with a large intra-abdominal jejunal GIST was treated with complete surgical resection followed by IM. The patient experienced disease recurrence 3.5 years later and underwent IM dose escalation and reresection.
CONCLUSION: Current strategies to treat recurrent GIST include dose escalation, modifying adjuvant tyrosine kinase inhibitor therapy, and surgery. High-level evidence will be required to better define the combinatory roles of tyrosine kinase inhibitor therapy, guided by molecular profiling, and surgery in the management of recurrent GIST.
Volume
2017
First Page
8349090
Last Page
8349090
ISSN
2090-6706
Published In/Presented At
Platoff, R. M., Morano, W. F., Marconcini, L., DeLeo, N., Mapow, B. L., Styler, M., & Bowne, W. B. (2017). Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease. Case reports in oncological medicine, 2017, 8349090. https://doi.org/10.1155/2017/8349090
Disciplines
Medicine and Health Sciences
PubMedID
29333308
Department(s)
Department of Pathology and Laboratory Medicine
Document Type
Article